Supplementary Table 1. Inclusion and exclusion criteria

A. Inclusion criteria	
1	Age 19–80 years
2	Independent individuals
3	Patients with type 2 diabetes mellitus and dyslipidemia at screening and baseline visits
4	Patients with type 2 diabetes mellitus; 6.5%≤ HbA1c ≤10.0% and dyslipidemia; 100≤ LDL-C ≤250 mg/dL at screening and baseline visits
5	Drug-naïve patients with type 2 diabetes mellitus or patients not taking hypoglycemic agents for the last 6 weeks
6	Drug-naïve patients with dyslipidemia or patients not taking lipid-lowering agents for the last 4 weeks (fenofibrate for 8 weeks)
7	Patients with more than 70% adherence to medication during a 4-week run-in period
B. Exclusion criteria	
1	BMI ≥35 or ≤18.5 kg/m^2
2	Patients with type 1 diabetes mellitus with or without a history of acute or chronic metabolic acidosis or ketonemia, including diabetic ketoacidosis
3	Patients with a history of myopathy, rhabdomyolysis, statin/fibric acid-related myopathy, hereditary myopathy, or family history of hereditary myopathy
4	Patients with secondary dyslipidemia related to nephrotic syndrome, hypothyroidism, dysproteinemia, cholestatic liver disease, Cushing's syndrome, etc.
5	Patients with uncontrolled hypertension; systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg
6	Patients with a history of coronary heart disease, like myocardial infarction, unstable angina, coronary artery bypass surgery, or coronary artery angioplasty within 6 months before enrolment
7	Patients with heart failure with NYHA class III or IV or congestive heart failure
8	Patients with malignancy (except for cases that have been cured or have not recurred within 5 years)
9	Patients with severe infection or severe post-traumatic sequelae
10	Patients with hypopituitarism or adrenal insufficiency
11	Patients with acute and chronic diseases causing tissue hypoxia, including respiratory failure, acute myocardial infarction, shock, etc.
12	Patients with gastrointestinal disorders including diarrhea, vomiting
13	Patients requiring intravenous administration of radioactive contrast media (e.g., intravenous urography, intravenous urography, intravenous cholangiography, intravenous angiography, contrast-enhanced computed tomography)
14	Patients with a history of side effects from metformin (biguanides) or atorvastatin
15	Patients with a genetic disease, like galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption
16	Patients with active or severe liver disease (AST/ALT ≥2.5 times the upper limit of normal)
17	Patients with severe renal disease or renal failure (serum creatinine ≥1.5 mg/dL [male patients], 1.4 mg/dL [female patients])
18	CK ≥2 times the upper limit of normal
19	Patients with uncontrolled thyroid function (TSH ≥ upper normal limit)
20	Serum triglyceride ≥400 mg/dL
21	Concurrent or previous use of GLP-1 agonist or insulin within 6 weeks
22	Patients with a history of treatment for obesity, including medication or bariatric surgery
23	Patients with a history of steroids in the previous 2 weeks
24	Use of prohibited concomitant medications
25	Pregnancy or breast-feeding at screening
26	History of drug or alcohol abuse
27	Inclusion in another clinical trial 3 months before screening
28	Patients determined by the investigator to be unsuitable for clinical trials

HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; NYHA, New York Heart Association; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatinine kinase; TSH, thyroid stimulating hormone; GLP-1, glucagon-like peptide-1.